Cancer research in the global village

The Lancet

Volumn 376, Issue 9742, 2010, Pages 659-660

  Munro, Alastair J ^a   Niblock, Paddy G ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

BREAST CANCER; CANCER RESEARCH; CANCER SURVIVAL; CANCER THERAPY; COLORECTAL CANCER; HEAD AND NECK CANCER; HEALTH CARE COST; HUMAN; NOTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH CANCER; TUMOR BIOPSY; GASTROINTESTINAL NEOPLASMS; INTERNATIONAL COOPERATION; NEOPLASMS; RESEARCH;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; GASTROINTESTINAL NEOPLASMS; HUMANS; INTERNATIONALITY; NEOPLASMS; RESEARCH;

EID: 77956268693     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(10)61022-7     Document Type: Note

References (10)

1. Y-J Bang, E Van Cutsem, A Feyereislova for the ToGA Trial Investigators Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial Lancet 2010 10.1016/S0140-6736(10)61121-X published online Aug 20.
2. JA Bonner, PM Harari, J Giralt Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck N Engl J Med 354 2006 567 578
3. JA Bonner, PM Harari, J Giralt Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival Lancet Oncol 11 2010 21 28
4. NC Tebbutt, K Wilson, VJ Gebski Capecitabine, bevacizumab and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized, Phase III MAX Study J Clin Oncol 28 2010 3191 3198
5. EH Romond, EA Perez, J Bryant Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer N Engl J Med 353 2005 1673 1684
6. H Grabsch, S Sivakumar, S Gray, HE Gabbert, W Muller HER2 expression in gastric cancer: rare, heterogeneous and of no prognostic value - conclusions from 924 cases of two independent series Cell Oncol 32 2010 57 65
7. CA Purdie, LB Jordan, JB McCullough HER2 assessment on core biopsy specimens using monoclonal antibody CB11 accurately determines HER2 status in breast carcinoma Histopathology 56 2010 702 707
8. G Sauter, G Lee, JM Bartlett, DJ Slamon, MF Press Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations J Clin Oncol 27 2009 1323 1333
9. National Institute for Health and Clinical Excellence Early and locally advanced breast cancer: diagnosis and treatment http://www.nice.org.uk/ nicemedia/pdf/CG80NICEGuideline.pdf February, 2009 (accessed July 23, 2010).
10. World Health Organisation, World health statistics 2010 WHO Press http://www.who.int/whosis/whostat/EN-WHS10-Full.pdf (accessed July 23, 2010).